[go: up one dir, main page]

FR2722208B1 - Nouveau site interne d'entree des ribosomes, vecteur le contenant et utilisation therapeutique - Google Patents

Nouveau site interne d'entree des ribosomes, vecteur le contenant et utilisation therapeutique

Info

Publication number
FR2722208B1
FR2722208B1 FR9408300A FR9408300A FR2722208B1 FR 2722208 B1 FR2722208 B1 FR 2722208B1 FR 9408300 A FR9408300 A FR 9408300A FR 9408300 A FR9408300 A FR 9408300A FR 2722208 B1 FR2722208 B1 FR 2722208B1
Authority
FR
France
Prior art keywords
vector containing
therapeutic use
entry site
internal ribosome
ribosome entry
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR9408300A
Other languages
English (en)
Other versions
FR2722208A1 (fr
Inventor
Clarisse Berlioz
Sabdrine Jacquemoud
Christophe Torrent
Jean Luc Darlix
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National de la Sante et de la Recherche Medicale INSERM
Original Assignee
Institut National de la Sante et de la Recherche Medicale INSERM
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR9408300A priority Critical patent/FR2722208B1/fr
Application filed by Institut National de la Sante et de la Recherche Medicale INSERM filed Critical Institut National de la Sante et de la Recherche Medicale INSERM
Priority to JP8503707A priority patent/JPH10503644A/ja
Priority to AU29295/95A priority patent/AU707874B2/en
Priority to EP95925007A priority patent/EP0769062A2/fr
Priority to US08/600,999 priority patent/US5925565A/en
Priority to CA002194155A priority patent/CA2194155A1/fr
Priority to PCT/FR1995/000894 priority patent/WO1996001324A2/fr
Publication of FR2722208A1 publication Critical patent/FR2722208A1/fr
Application granted granted Critical
Publication of FR2722208B1 publication Critical patent/FR2722208B1/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13051—Methods of production or purification of viral material
    • C12N2740/13052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/90—Vectors containing a transposable element
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/788—Of specified organic or carbon-based composition
    • Y10S977/802—Virus-based particle
    • Y10S977/803—Containing biological material in its interior
    • Y10S977/804—Containing nucleic acid
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/915—Therapeutic or pharmaceutical composition
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/92—Detection of biochemical

Landscapes

  • Genetics & Genomics (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
FR9408300A 1994-07-05 1994-07-05 Nouveau site interne d'entree des ribosomes, vecteur le contenant et utilisation therapeutique Expired - Fee Related FR2722208B1 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
FR9408300A FR2722208B1 (fr) 1994-07-05 1994-07-05 Nouveau site interne d'entree des ribosomes, vecteur le contenant et utilisation therapeutique
AU29295/95A AU707874B2 (en) 1994-07-05 1995-07-05 New internal ribosome entry site, vector containing it and therapeutical use
EP95925007A EP0769062A2 (fr) 1994-07-05 1995-07-05 Nouveau site interne d'entree des ribosomes, vecteur le contenant et utilisation therapeutique
US08/600,999 US5925565A (en) 1994-07-05 1995-07-05 Internal ribosome entry site, vector containing it and therapeutic use
JP8503707A JPH10503644A (ja) 1994-07-05 1995-07-05 新規な内部リボソーム侵入部位、これを含むベクター、および治療への使用
CA002194155A CA2194155A1 (fr) 1994-07-05 1995-07-05 Nouveau site interne d'entree des ribosomes, vecteur le contenant et utilisation therapeutique
PCT/FR1995/000894 WO1996001324A2 (fr) 1994-07-05 1995-07-05 Nouveau site interne d'entree des ribosomes, vecteur le contenant et utilisation therapeutique

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9408300A FR2722208B1 (fr) 1994-07-05 1994-07-05 Nouveau site interne d'entree des ribosomes, vecteur le contenant et utilisation therapeutique

Publications (2)

Publication Number Publication Date
FR2722208A1 FR2722208A1 (fr) 1996-01-12
FR2722208B1 true FR2722208B1 (fr) 1996-10-04

Family

ID=9465025

Family Applications (1)

Application Number Title Priority Date Filing Date
FR9408300A Expired - Fee Related FR2722208B1 (fr) 1994-07-05 1994-07-05 Nouveau site interne d'entree des ribosomes, vecteur le contenant et utilisation therapeutique

Country Status (7)

Country Link
US (1) US5925565A (fr)
EP (1) EP0769062A2 (fr)
JP (1) JPH10503644A (fr)
AU (1) AU707874B2 (fr)
CA (1) CA2194155A1 (fr)
FR (1) FR2722208B1 (fr)
WO (1) WO1996001324A2 (fr)

Families Citing this family (184)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6605712B1 (en) * 1990-12-20 2003-08-12 Arch Development Corporation Gene transcription and ionizing radiation: methods and compositions
US6958237B2 (en) 1991-06-28 2005-10-25 Georgia State Univesity Research Foundation, Inc. Highly infectious rubella virus DNA constructs and methods of production
US20030215795A1 (en) * 1991-06-28 2003-11-20 Frey Teryl K. Highly infectious rubella virus DNA constructs and methods of production
DE19514310A1 (de) * 1995-04-18 1996-10-24 Univ Ludwigs Albert Vektoren zur Transfektion von eukaryotischen Zellen, deren Verwendung und damit transfizierte Zielzellen
FR2747046B1 (fr) * 1996-04-05 1998-06-19 Univ Paris Curie Nouveaux vaccins issus de plasmovirus
FR2755975B1 (fr) * 1996-11-15 1999-05-07 Rhone Poulenc Rorer Sa Virus recombinants bicistroniques utiles pour le traitement de pathologies liees aux dyslipoproteinemies
FR2757061B1 (fr) * 1996-12-16 1999-03-26 Rhone Merieux Vaccin vivant recombinant aviaire, utilisant comme vecteur le virus de la laryngotracheite infectieuse aviaire
FR2762615B1 (fr) * 1997-04-28 1999-07-16 Inst Nat Sante Rech Med Nouveau site interne d'entree des ribosomes et vecteur le contenant
FR2766091A1 (fr) 1997-07-18 1999-01-22 Transgene Sa Composition antitumorale a base de polypeptide immunogene de localisation cellulaire modifiee
AU1591099A (en) 1997-11-19 1999-06-07 Nature Technology, Inc. Chimeric viral packaging signal without (gag) gene sequences
US20030138808A1 (en) * 1998-02-19 2003-07-24 Simard John J.L. Expression vectors encoding epitopes of target-associated antigens
JP2002506651A (ja) * 1998-03-16 2002-03-05 イントロジェン・セラピューティクス，インコーポレイテッド 多重遺伝子ベクター
AU1128400A (en) 1998-10-22 2000-05-08 Medical College Of Georgia Institute, Inc. Long terminal repeat, enhancer, and insulator sequences for use in recombinant vectors
US6924099B1 (en) * 1999-01-29 2005-08-02 G.D. Searle & Co. Biomarkers and assays for carcinogenesis
WO2000066758A1 (fr) * 1999-04-29 2000-11-09 Aarhus University Expression de genes heterologues, a partir d'une cassette de traduction ires, dans des vecteurs retroviraux
DE60041183D1 (de) 1999-05-06 2009-02-05 Univ Wake Forest Zusammensetzungen und methoden zur identifikation von antigenen, die eine immunantwort hervorrufen
ATE490777T1 (de) 1999-06-01 2010-12-15 Baylor College Medicine Zusammensetzungen und verfahren zur therapeutischen anwendung einer mit dem gen atonal assoziierten sequenz
US20030215425A1 (en) * 2001-12-07 2003-11-20 Simard John J. L. Epitope synchronization in antigen presenting cells
AU5741001A (en) * 2000-04-28 2001-11-12 Ctl Immunotherapies Corp Epitope synchronization in antigen presenting cells
US6861234B1 (en) 2000-04-28 2005-03-01 Mannkind Corporation Method of epitope discovery
WO2002014492A2 (fr) * 2000-08-14 2002-02-21 Iogenetics, Llc Bovins resistant au syndrome de la vache grasse
WO2002022839A2 (fr) * 2000-09-15 2002-03-21 Institut National De La Sante Et De La Recherche Medicale (Inserm) Sites d'entree ribosome interne (ires) d'errantivirus et leurs utilisations
US7575924B2 (en) 2000-11-13 2009-08-18 Research Development Foundation Methods and compositions relating to improved lentiviral vectors and their applications
US20040242523A1 (en) * 2003-03-06 2004-12-02 Ana-Farber Cancer Institue And The Univiersity Of Chicago Chemo-inducible cancer gene therapy
ES2380007T3 (es) * 2001-04-06 2012-05-07 The University Of Chicago Inducción por agentes quimioterapéuticos de la actividad del promotor Egr-1 en la terapia génica
US8034791B2 (en) 2001-04-06 2011-10-11 The University Of Chicago Activation of Egr-1 promoter by DNA damaging chemotherapeutics
EP1412493B1 (fr) 2001-08-02 2011-10-05 Institut Clayton De La Recherche Procedes et compositions relatifs a des systemes production ameliores de vecteurs lentiviraux
US20030129203A1 (en) * 2001-08-27 2003-07-10 Nautilus Biotech S.A. Mutant recombinant adeno-associated viruses
US7647184B2 (en) * 2001-08-27 2010-01-12 Hanall Pharmaceuticals, Co. Ltd High throughput directed evolution by rational mutagenesis
US20030157717A1 (en) * 2001-09-07 2003-08-21 Baylor College Of Medicine Texas Medical Center Linear DNA fragments for gene expression
EP1438075A4 (fr) * 2001-10-02 2006-04-19 Inst Clayton De La Rech Procedes et compositions se rapportant a des vecteurs lentiviraux a expression reduite et leurs applications
EP1450605B1 (fr) 2001-10-26 2011-12-07 Baylor College Of Medicine Composition permettant de modifier les proprietes osseuses d'un sujet
AU2002353970A1 (en) * 2001-11-02 2003-05-19 Rice University Recycling system for manipulation of intracellular nadh availability
CN1313617C (zh) * 2001-11-07 2007-05-02 曼康公司 编码靶相关抗原表位的表达载体及其设计方法
US20030157641A1 (en) * 2001-11-16 2003-08-21 Idec Pharmaceuticals Corporation Polycistronic expression of antibodies
EP1465654B1 (fr) 2001-12-11 2015-02-25 Inovio Pharmaceuticals, Inc. Supplementation induite par les plasmides dans le traitement de maladies chroniques affectant des sujets
US20030224404A1 (en) * 2002-02-25 2003-12-04 Manuel Vega High throughput directed evolution of nucleic acids by rational mutagenesis
DE60326444D1 (de) * 2002-04-26 2009-04-16 Inst Clayton De La Rech Verbesserte chimäre glykoproteine und pseudotypisierte lentivirale vektoren
EP1501861A4 (fr) 2002-05-06 2007-06-20 Univ Texas Ciblage de proteines pour l'apport de reactifs therapeutiques ou de diagnostic
CN1754002B (zh) 2002-08-12 2010-09-08 杰能斯有限公司 涉及痘病毒和癌的组合物及制备方法
US20050202438A1 (en) * 2002-09-09 2005-09-15 Rene Gantier Rational directed protein evolution using two-dimensional rational mutagenesis scanning
WO2004022593A2 (fr) 2002-09-09 2004-03-18 Nautilus Biotech Evolution rationnelle de cytokines pour une plus grande stabilite, les cytokines et molecules d'acide nucleique codant
US20060020396A1 (en) * 2002-09-09 2006-01-26 Rene Gantier Rational directed protein evolution using two-dimensional rational mutagenesis scanning
CA2506798C (fr) * 2002-11-22 2013-01-22 Institut Clayton De La Recherche Compositions et systemes destines a la regulation genique
EP1641927B1 (fr) 2003-02-18 2015-07-08 Baylor College of Medicine Activation induite dans des cellules dendritiques
US8481504B2 (en) 2003-03-12 2013-07-09 Vgx Pharmaceuticals, Inc. Insulin-like growth factor (IGF-I) plasmid-mediated supplementation for therapeutic applications
TW200424214A (en) * 2003-04-21 2004-11-16 Advisys Inc Plasmid mediated GHRH supplementation for renal failures
CA2531698A1 (fr) 2003-07-09 2005-01-27 Sentigen Biosciences, Inc. Methode de detection d'une interaction proteine-proteine
US20070224615A1 (en) * 2003-07-09 2007-09-27 Invitrogen Corporation Methods for assaying protein-protein interactions
ATE405654T1 (de) 2003-07-21 2008-09-15 Transgene Sa Polypeptid mit verbesserter cytosin-deaminase- aktivität
WO2005047473A2 (fr) * 2003-11-10 2005-05-26 Emory University Bitherapie genique a un seul vecteur pour hypertension pulmonaire
CA2592891C (fr) 2003-12-31 2013-05-28 Advisys, Inc. Reduction de l'arthrite et de la boiterie chez des sujets par apport complementaire de somatostatine (srif)
US7998930B2 (en) 2004-11-04 2011-08-16 Hanall Biopharma Co., Ltd. Modified growth hormones
TW200745332A (en) 2005-07-21 2007-12-16 Abbott Lab Multiple gene expression including sorf constructs and methods with polyproteins, pro-proteins, and proteolysis
US20070026012A1 (en) 2005-08-01 2007-02-01 Cornell Research Foundation, Inc. Compositions and methods for monitoring and altering protein folding and solubility
US8980246B2 (en) 2005-09-07 2015-03-17 Sillajen Biotherapeutics, Inc. Oncolytic vaccinia virus cancer therapy
EP2368569A3 (fr) 2006-01-18 2012-05-02 University Of Chicago Compositions et procédés liés aux protéines des bactéries staphylocoques
US20080096228A1 (en) * 2006-08-08 2008-04-24 The Regents Of The University Of California Compositions And Methods Relating To Mammalian Internal Ribosome Entry Sites
WO2009016433A2 (fr) 2006-09-15 2009-02-05 Ottawa Health Research Institute Rhabdovirus oncolytique
EP2465511B1 (fr) 2006-10-19 2019-05-22 Baylor College Of Medicine Procédés et compositions de génération d'une réponse immunitaire par l'induction de CD40 et récepteurs de reconnaissance de motif et adaptateurs associés
KR20080084528A (ko) 2007-03-15 2008-09-19 제네렉스 바이오테라퓨틱스 인크. 종양살상형 백시니아 바이러스 암 치료
CN101743306A (zh) 2007-03-23 2010-06-16 威斯康星校友研究基金会 体细胞重编程
MX2010007530A (es) 2008-01-10 2010-11-10 Res Dev Foundation Vacunas y diagnosticos para ehrlichiosis.
CA2716801A1 (fr) * 2008-03-12 2009-09-17 Wyeth Llc Procede pour identifier des cellules appropriees pour une production a grande echelle de proteines recombinantes
EP2279253B1 (fr) 2008-04-09 2016-11-16 Maxcyte, Inc. Préparation et administration de compositions thérapeutiques de cellules fraîchement isolées
DK2297307T3 (en) 2008-06-04 2016-07-25 Cellular Dynamics Int Inc PROCEDURES FOR THE MANUFACTURE OF IPS CELLS USING NON-VIRAL METHODS
EP3330371A1 (fr) * 2008-08-12 2018-06-06 Cellular Dynamics International, Inc. Procédés de production de cellules ips
EP2328603A4 (fr) 2008-08-18 2013-01-02 Univ Maryland Dérivés d'apf et méthodes d'utilisation afférentes
EP2331680B1 (fr) * 2008-09-22 2017-05-03 Baylor College Of Medicine Procédés et compositions permettant la génération d'une réponse immunitaire par l'induction de cd40 et adaptateur de récepteurs de reconnaissance de motifs
CN102333540B (zh) 2008-10-06 2015-04-22 芝加哥大学 与细菌eap、emp和/或adsa蛋白相关的组合物和方法
KR20170102039A (ko) 2009-04-03 2017-09-06 유니버시티 오브 시카고 단백질 Ａ(ＳｐＡ) 변이체와 관련된 조성물 및 방법
EP2438160B1 (fr) 2009-06-05 2015-12-23 Cellular Dynamics International, Inc. Reprogrammation de lymphocytes t et de cellules hématopoïétiques
KR101838472B1 (ko) 2009-09-14 2018-03-15 신라젠(주) 종양 용해 백시니아 바이러스 병용 암 치료요법
KR20120091251A (ko) * 2009-10-30 2012-08-17 아보트 러보러터리즈 Ｓｏｒｆ 작제물 및 다중 유전자 발현
EP2510088B1 (fr) 2009-12-10 2016-10-05 Ottawa Hospital Research Institute Rhabdovirus oncolitique
US10080799B2 (en) 2010-02-12 2018-09-25 Arizona Board Of Regents On Behalf Of Arizona State University Methods and compositions related to glycoprotein-immunoglobulin fusions
EP2548030B1 (fr) 2010-03-18 2015-05-27 Cornell University Préparation d'anticorps correctement pliés utilisant la présentation sur la membrane intérieure d'intermédiaires de translocation twin-arginine
JP2013523818A (ja) 2010-04-05 2013-06-17 ザ・ユニバーシティー・オブ・シカゴ 免疫反応のエンハンサーとしてのプロテインＡ（ＳｐＡ）抗体に関連する組成物および方法
US8785385B2 (en) 2010-04-19 2014-07-22 Research Development Foundation RTEF-1 variants and uses thereof
US9089520B2 (en) 2010-05-21 2015-07-28 Baylor College Of Medicine Methods for inducing selective apoptosis
CA2802249A1 (fr) 2010-06-15 2011-12-22 Cellular Dynamics International, Inc. Generation de cellules souches pluripotentes induites a partir de petits volumes de sang peripherique
JP2013530699A (ja) 2010-06-15 2013-08-01 セルラー ダイナミクス インターナショナル， インコーポレイテッド 生物学的応答の調査のための既製の幹細胞モデルの概要
CA2803298C (fr) 2010-07-02 2020-07-14 The University Of Chicago Compositions et methodes associees a des variants de proteine a (spa)
US8785192B2 (en) 2010-07-07 2014-07-22 Cellular Dynamics International, Inc. Endothelial cell production by programming
US8765470B2 (en) 2010-08-04 2014-07-01 Cellular Dynamics International, Inc. Reprogramming immortalized B-cells to induced pluripotent stem cells
US9731023B2 (en) 2010-09-08 2017-08-15 Board Of Regents, The University Of Texas System Somatostatin receptor-based cancer therapy
US9095540B2 (en) 2010-09-09 2015-08-04 The University Of Chicago Methods and compositions involving protective staphylococcal antigens
WO2012047099A2 (fr) * 2010-10-04 2012-04-12 Bedrijfslaboratorium Voor Grond-En Gewasonderzoek B.V. Méthode d'extraction d'adn de cellules végétales et de nématodes
KR101942237B1 (ko) 2011-01-04 2019-01-25 신라젠(주) 종양 항원에 대한 항체의 생산 및 종양용해 우두 바이러스의 투여에 의한 종양 특이적 보체 의존적 세포독성의 생산
WO2012098260A1 (fr) 2011-01-21 2012-07-26 Axiogenesis Ag Système non viral pour générer des cellules souches pluripotentes induites (ips)
CA2826386C (fr) 2011-02-08 2020-04-28 Cellular Dynamics International, Inc. Production de precurseurs hematopoietiques obtenus par programmation
EP3406628A1 (fr) 2011-04-08 2018-11-28 Evaxion Biotech ApS Protéines et acides nucléiques utiles dans des vaccins ciblant le staphylococcus aureus
US8945588B2 (en) 2011-05-06 2015-02-03 The University Of Chicago Methods and compositions involving protective staphylococcal antigens, such as EBH polypeptides
CA2872045A1 (fr) 2011-06-08 2012-12-13 Children's Hospital Of Eastern Ontario Research Institute Inc. Compositions et procedes pour le traitement du glioblastome
EP2732029B1 (fr) 2011-07-11 2019-01-16 FUJIFILM Cellular Dynamics, Inc. Procédés de reprogrammation cellulaire et d'ingénierie génomique
WO2013026015A1 (fr) 2011-08-18 2013-02-21 Dana-Farber Cancer Institute, Inc. Pièges de ligand de muc1 pour l'utilisation dans le traitement de cancers
EP2766388A1 (fr) 2011-10-12 2014-08-20 Møller, Niels Iversen Peptides dérivés de campylobacter jejuni et leur utilisation en vaccination
KR102100092B1 (ko) 2012-02-02 2020-04-13 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 이종 종양-관련 항원들을 발현하는 아데노바이러스
ES2806945T3 (es) 2012-04-26 2021-02-19 Univ Chicago Antígenos de coagulasa estafilocócica y métodos para su uso
US10125373B2 (en) 2013-01-22 2018-11-13 Arizona Board Of Regents On Behalf Of Arizona State University Geminiviral vector for expression of rituximab
MX2015010783A (es) 2013-02-21 2016-06-21 Children S Hospital Of Eastern Ontario Res Inst Inc Composicion de vacuna.
AU2014218807A1 (en) 2013-02-22 2015-09-03 Cellular Dynamics International, Inc. Hepatocyte production via forward programming by combined genetic and chemical engineering
WO2014132137A2 (fr) 2013-03-01 2014-09-04 Université De Genève Sélection de cellules transgéniques
US9434935B2 (en) 2013-03-10 2016-09-06 Bellicum Pharmaceuticals, Inc. Modified caspase polypeptides and uses thereof
US9944690B2 (en) 2013-03-14 2018-04-17 Bellicum Pharmaceuticals, Inc. Methods for controlling T cell proliferation
US12060396B2 (en) 2013-04-11 2024-08-13 Vanderbilt University Fused in sarcoma (FUS) nuclear translocation inhibitors for preventing fibrosis
DK3004329T3 (da) 2013-06-05 2020-05-18 Bellicum Pharmaceuticals Inc Fremgangsmåder til induktion af delvis apoptose under anvendelse af caspasepolypeptider
CN105636614A (zh) 2013-09-09 2016-06-01 菲格内有限责任公司 用于软骨细胞或软骨型细胞再生的基因治疗
US20170002064A1 (en) 2013-11-08 2017-01-05 The Board Of Regents Of The University Of Texas System Vh4 antibodies against gray matter neuron and astrocyte
US10028902B2 (en) 2013-11-08 2018-07-24 Baylor Research Institute Nuclear localization of GLP-1 stimulates myocardial regeneration and reverses heart failure
DK3071697T3 (da) 2013-11-22 2020-01-27 Dnatrix Inc Adenovirus der udtrykker immuncelle-stimulatorisk(e) receptor agonist(er)
EP4227685A3 (fr) 2013-12-03 2024-02-28 Evaxion Biotech A/S Proteines et acides nucleiques utiles dans des vaccins ciblant staphylococcus aureus
US10059775B2 (en) 2014-01-29 2018-08-28 Dana-Farber Cancer Institute, Inc. Antibodies against the MUC1-C/extracellular domain (MUC1-C/ECD)
JP6772063B2 (ja) 2014-02-14 2020-10-21 ベリカム ファーマシューティカルズ， インコーポレイテッド 誘導可能なキメラポリペプチドを使用して細胞を活性化するための方法
EP3154350B1 (fr) 2014-04-10 2024-03-27 H. Lee Moffitt Cancer Center And Research Institute, Inc. Expansion améliorée des lymphocytes infiltrants des tumeurs pour thérapie cellulaire adoptive
WO2015164228A1 (fr) 2014-04-21 2015-10-29 Cellular Dynamics International, Inc. Production d'hépatocytes par programmation progressive par génie génétique et chimique combinés
AU2015287833B2 (en) 2014-07-08 2018-09-13 The Children's Medical Center Corporation Compositions and methods for treating diabetes
US10888608B2 (en) 2014-09-02 2021-01-12 Bellicum Pharmaceuticals, Inc. Costimulation of chimeric antigen receptors by MyD88 and CD40 polypeptides
CA2966300C (fr) 2014-11-03 2023-07-11 Mirjam H.M. Heemskerk Recepteurs de cellules t dirigees contre bob1 et leurs utilisations
US20180169211A1 (en) 2014-11-13 2018-06-21 Evaxion Biotech Aps Peptides derived from acinetobacter baumannii and their use in vaccination
CA2969145A1 (fr) 2014-11-26 2016-06-02 The Regents Of The University Of California Compositions therapeutiques comprenant des facteurs de transcription et leurs procedes de preparation et d'utilisation
US20160175359A1 (en) 2014-12-15 2016-06-23 Bellicum Pharmaceuticals, Inc. Methods for controlled activation or elimination of therapeutic cells
EP3485907B1 (fr) 2015-01-12 2023-06-28 Evaxion Biotech ApS Traitement et prophylaxie d'une infection k. pneumoniae
WO2016134293A1 (fr) 2015-02-20 2016-08-25 Baylor College Of Medicine Inactivation de p63 pour le traitement de l'insuffisance cardiaque
AU2016230828B2 (en) 2015-03-10 2020-10-22 ACADEMISCH ZIEKENHUIS LEIDEN (h.o.d.n. LUMC) T-cell receptors directed against the preferentially expressed antigen of melanoma and uses thereof
WO2017005670A1 (fr) 2015-07-04 2017-01-12 Evaxion Biotech Aps Protéines et acides nucléiques utiles dans des vaccins ciblant pseudomonas aeruginosa
ES2862676T3 (es) 2015-10-20 2021-10-07 Fujifilm Cellular Dynamics Inc Producción de células precursoras hematopoyéticas multilinaje mediante programación genética
WO2017075395A1 (fr) 2015-10-28 2017-05-04 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Vecteurs adénoviraux à spécificité tumorale et leurs utilisations thérapeutiques
JP6983771B2 (ja) 2015-10-30 2021-12-17 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニアThe Regents Of The University Of California 幹細胞からｔ細胞を作製する方法および該ｔ細胞を用いた免疫療法的方法
US11594135B2 (en) 2015-11-02 2023-02-28 Memgen, Inc. Methods of CD40 activation and immune checkpoint blockade
CN108884159A (zh) 2015-11-07 2018-11-23 茂体外尔公司 用于癌症治疗的包含肿瘤抑制基因治疗和免疫检查点阻断的组合物
SI3373968T1 (sl) 2015-11-09 2024-10-30 The Children's Hospital Of Philadelphia Glipikan 2 kot marker raka in terapevtska tarča
EP3419654B1 (fr) 2016-02-22 2022-04-27 Evaxion Biotech A/S Protéines et acides nucléiques utiles dans des vaccins ciblant staphylococcus aureus
WO2017168348A1 (fr) 2016-03-31 2017-10-05 Baylor Research Institute Protéine 8 de type angiopoïétine (angptl8)
EP3463449A1 (fr) 2016-05-27 2019-04-10 ALK-Abelló A/S Protéines immunogènes et fragments de celles-ci à partir d'acariens allergènes
WO2017216384A1 (fr) 2016-06-17 2017-12-21 Evaxion Biotech Aps Vaccination ciblant ichthyophthirius multifiliis
WO2017220787A1 (fr) 2016-06-24 2017-12-28 Evaxion Biotech Aps Vaccin contre l'infection provoquée par aeromonas salmonicida
US20180030478A1 (en) 2016-07-01 2018-02-01 Research Development Foundation Elimination of proliferating cells from stem cell-derived grafts
WO2018015575A1 (fr) 2016-07-22 2018-01-25 Evaxion Biotech Aps Protéines chimériques pour induire une immunité vis-à-vis d'une infection à s. aureus
CA3038701A1 (fr) 2016-10-05 2018-04-12 FUJIFILM Cellular Dynamics, Inc. Procedes de differenciation dirigee de cellules souches pluripotentes en cellules immunes homozygotes hla
JP7418796B2 (ja) 2016-11-03 2024-01-22 テンプル・ユニバーシティ－オブ・ザ・コモンウェルス・システム・オブ・ハイアー・エデュケイション 細胞株の開発のための相同組換えベクターの高速生成のためのｄｎａプラスミド
WO2018087720A1 (fr) 2016-11-14 2018-05-17 Novartis Ag Compositions, méthodes et utilisations thérapeutiques associées à une protéine fusogène minion
CN110381997A (zh) 2016-12-12 2019-10-25 茂体外尔公司 用于治疗和预防癌症和感染性疾病的包含病毒基因治疗和免疫检查点抑制剂的方法和组合物
KR20190098215A (ko) 2016-12-21 2019-08-21 멤젠 엘엘씨 무장된 복제-가능 종양 분해 아데노바이러스
US11298420B2 (en) 2016-12-21 2022-04-12 Memgen, Llc Armed oncolytic viruses
US11718648B2 (en) 2017-01-05 2023-08-08 Evaxion Biotech A/S Vaccines targeting Pseudomonas aeruginosa
DE102017103383A1 (de) 2017-02-20 2018-08-23 aReNA-Bio GbR (vertretungsberechtigter Gesellschafter: Dr. Heribert Bohlen, 50733 Köln) System und Verfahren zur Zelltyp-spezifischen Translation von RNA-Molekülen in Eukaryoten
EP3385373A1 (fr) 2017-04-05 2018-10-10 Centro de Neurociências e Biologia Celular Compositions pour la reprogrammation de cellules en cellules dendritiques ou en cellules présentatrices d'antigènes, leurs procédés et utilisations
WO2018185709A1 (fr) 2017-04-05 2018-10-11 Centro De Neurociencias E Biologia Celular Compositions destinées à la reprogrammation de cellules en cellules dendritiques ou en cellules présentatrices d'antigène, procédés et utilisations associés
AU2018254442B2 (en) 2017-04-18 2024-03-28 FUJIFILM Cellular Dynamics, Inc. Antigen-specific immune effector cells
US20210147507A1 (en) 2017-05-09 2021-05-20 Bellicum Pharmaceuticals, Inc. Methods to augment or alter signal transduction
KR20200032722A (ko) 2017-07-27 2020-03-26 노파르티스 아게 부분절단효소 내성 trem2 변이체
WO2019094938A2 (fr) 2017-11-13 2019-05-16 The University Of Chicago Méthodes et compositions pour le traitement des plaies
WO2019145399A1 (fr) 2018-01-24 2019-08-01 Evaxion Biotech Aps Vaccins pour la prophylaxie d'infections par s. aureus
JP2021518408A (ja) 2018-03-19 2021-08-02 マルチビア インコーポレイテッド 癌治療のための、癌抑制遺伝子治療法及びｃｄ１２２／ｃｄ１３２アゴニストを含む、方法及び組成物
WO2019183500A1 (fr) 2018-03-23 2019-09-26 Hung Chiung Yu Antigènes de coccidioides et leurs procédés d'utilisation
WO2019211320A1 (fr) 2018-05-01 2019-11-07 Orfoneuro Aps Traitement de la céroïde-lipofuscinose neuronale
JP7450945B2 (ja) 2018-08-30 2024-03-18 テナヤ セラピューティクス， インコーポレイテッド ミオカルディンおよびａｓｃｌ１を用いた心細胞リプログラミング
US20220111031A1 (en) 2018-10-22 2022-04-14 Evaxion Biotech Aps Vaccines targeting M. catharrhalis
EP3930687A4 (fr) 2019-02-25 2023-06-07 The University of Chicago Méthodes et compositions destinées au traitement de maladies auto-immunes et inflammatoires faisant intervenir des peptides à affinité pour la matrice extracellulaire liés à des agents anti-inflammatoires
EP3931206A1 (fr) 2019-02-27 2022-01-05 Evaxion Biotech ApS Vaccins ciblant h. influenzae
WO2020205889A1 (fr) 2019-04-01 2020-10-08 Tenaya Therapeutics, Inc. Virus adéno-associé comprenant une capside modifiée
EP3997226A1 (fr) 2019-07-11 2022-05-18 Tenaya Therapeutics, Inc. Reprogrammation de cellules cardiaques avec des microarn et d'autres facteurs
US20220257653A1 (en) 2019-07-19 2022-08-18 The Children's Hospital Of Philadelphia Chimeric antigen receptors containing glypican 2 binding domains
EP4028763A1 (fr) 2019-09-13 2022-07-20 Evaxion Biotech A/S Procédé d'identification d'épitopes de lymphocytes t
WO2021048381A1 (fr) 2019-09-13 2021-03-18 Evaxion Biotech Aps Procédé d'identification de peptides de liaison au cmh stable par spectrométrie de masse
WO2021113644A1 (fr) 2019-12-05 2021-06-10 Multivir Inc. Combinaisons comprenant un activateur de lymphocytes t cd8+, un inhibiteur de point de contrôle immunitaire et une radiothérapie en vue d'obtenir des effets ciblés et abscopal pour le traitement du cancer
WO2021140123A1 (fr) 2020-01-06 2021-07-15 Evaxion Biotech Aps Vaccins ciblant neisseria gonorrhoeae
EP4114421A1 (fr) 2020-03-02 2023-01-11 Tenaya Therapeutics, Inc. Régulation de vecteur génique au moyen de micro-arn exprimés par des cardiomyocytes
EP4127148A1 (fr) 2020-03-25 2023-02-08 Erasmus University Rotterdam Medical Center Système rapporteur pour imagerie de radionucléides
JP2023536210A (ja) 2020-05-29 2023-08-24 フジフィルム セルラー ダイナミクス，インコーポレイテッド 網膜色素上皮及び光受容体の二重層、並びにその使用
US20230201267A1 (en) 2020-05-29 2023-06-29 FUJIFILM Cellular Dynamics, Inc. Retinal pigmented epithelium and photoreceptor dual cell aggregates and methods of use thereof
AU2021360902A1 (en) 2020-10-15 2023-04-27 Aavocyte, Inc. Recombinant adeno-associated virus vectors with cd14 promoter and use thereof
WO2022173767A1 (fr) 2021-02-09 2022-08-18 University Of Houston System Virus oncolytique pour l'administration systémique et les activités anti-tumorales améliorées
BR112023021993A2 (pt) 2021-05-03 2024-02-20 Astellas Inst For Regenerative Medicine Métodos de geração de células endoteliais da córnea madura
EP4334435A1 (fr) 2021-05-07 2024-03-13 Astellas Institute for Regenerative Medicine Procédés de génération d'hépatocytes matures
WO2022248531A1 (fr) 2021-05-26 2022-12-01 Evaxion Biotech A/S Vaccination ciblant des pathogènes intracellulaires
US20220389436A1 (en) 2021-05-26 2022-12-08 FUJIFILM Cellular Dynamics, Inc. Methods to prevent rapid silencing of genes in pluripotent stem cells
CN117915944A (zh) 2021-07-05 2024-04-19 伊沃逊生物科技股份公司 靶向淋病奈瑟氏菌的疫苗
AU2023215791A1 (en) 2022-02-07 2024-07-25 Var2 Pharmaceuticals Aps Antibodies and antibody fragments and analogues specific for chondroitin sulfate
WO2023178191A1 (fr) 2022-03-16 2023-09-21 University Of Houston System Système d'administration de gène hsv persistant
EP4508062A1 (fr) 2022-04-11 2025-02-19 Tenaya Therapeutics, Inc. Virus adéno-associé comprenant une capside modifiée
AU2022457212A1 (en) 2022-05-04 2024-11-14 Evaxion Biotech A/S Staphylococcal protein variants and truncates
AU2023298141A1 (en) 2022-06-29 2024-12-05 FUJIFILM Cellular Dynamics, Inc. Ipsc-derived astrocytes and methods of use thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE169061T1 (de) * 1990-10-25 1998-08-15 Clague Pitman Hodgson Methode des gentransfers mittels retrotransposons
ATE213779T1 (de) * 1991-08-07 2002-03-15 W French Anderson Interne ribosom eintrittsstellen enthaltene retrovirale vektoren

Also Published As

Publication number Publication date
WO1996001324A2 (fr) 1996-01-18
CA2194155A1 (fr) 1996-01-18
US5925565A (en) 1999-07-20
AU2929595A (en) 1996-01-25
WO1996001324A3 (fr) 1996-02-29
FR2722208A1 (fr) 1996-01-12
AU707874B2 (en) 1999-07-22
JPH10503644A (ja) 1998-04-07
EP0769062A2 (fr) 1997-04-23

Similar Documents

Publication Publication Date Title
FR2722208B1 (fr) Nouveau site interne d'entree des ribosomes, vecteur le contenant et utilisation therapeutique
DE69415163D1 (de) ZUZAMMENSETUNG ENTHALTEND 1,1,1,2,3,4,4,5,5,5,-DECAFLUORPENTAN UND n-PROPANOL
NO305952B1 (no) 1,5-benzodiazepinderivater, anvendelse derav og farmasoeytiske preparater
DE69611813D1 (de) Trokar und Kanüle
MA23895A1 (fr) Amides therapeutiques et compositions les contenant
DE59509233D1 (de) Kosmetische und dermatologische zubereitungen, enthaltend phenylen-1,4-bisbenzimidiazolesulfonsäuren
FR2592048B1 (fr) Inhibiteurs d'ureido-renine, a action therapeutique
IS4345A (is) Setin N-(indól-2-karbónýl)-b-alaninamíð, notkun þeirra og lyfjaefnablöndur
IL113844A (en) N-(alpha-ETHYLBENZYL)-3-HYDROXY-2-PHENYLQUINOLINE-4-CARBOXAMIDE AND ITS USE IN THE PREPARATION OF MEDICAMENTS
DE69432971D1 (de) Trokar und kanüle
KR970000221A (ko) 약물 및 화장품의 국소 전달을 위한 트리코-형 파우치
HUP0100042A3 (en) Benzofuran carboxamides medicaments containing the same and their therapeutic use
ITRM940706A0 (it) "isochinoline"
DE69219238D1 (de) Dichter-Einsatz
FR2762615B1 (fr) Nouveau site interne d'entree des ribosomes et vecteur le contenant
HU9601250D0 (en) Biologically active silicon-compounds and their pharmaceutical and cosmetical use
HU9501763D0 (en) 4-benzoyl isoxazole derivatives and their use as herbicides
FR2758329B1 (fr) Derives d'imidazole-4-butane boronique, leur preparation et leur utilisation en therapeutique
FR2735132B1 (fr) Medicament polypeptidique modifie, composition et dispositif d'administration par electrotransport le contenant
GR900100468A (en) Hair treatment shampoo comprising alcohole
DE59306085D1 (de) Haar- und körperbehandlungsmittel
FR2697977B1 (fr) Appareil d'épilation.
MX9200851A (es) Paquete de pañuelo desechable facial.
ITTO970974A0 (it) Utilizzo di un agente chimico per diminuire le variazioni di giro di vita e l'effetto di costipazione legato all'assunzione di altri agenti
FR2680653B1 (fr) Appareil d'epilation.

Legal Events

Date Code Title Description
ST Notification of lapse